NeOncoFRAx is a company with a strong connection to Erasmus MC’s research organization. We believe that every patient should have access to potentially life-saving, personalized cancer immunotherapies, regardless of socioeconomic background. The team that works on these therapies combines scientific rigor with clinical compassion to ensure the safe, rapid, and effective development of personalized vaccines for solid tumors, starting with pancreatic cancer.
Meet the Team
We are committed to developing a safe, effective, and accessible treatment for patients with resected pancreatic cancer. Our aim is not only scientific excellence, but also equitable access, ensuring the vaccine reaches patients at an affordable cost and without delay.
We pursue this mission by:
NeOncoFRAx was founded through a visionary act of patient-driven philanthropy. When Frank Snijders was diagnosed with advanced pancreatic cancer, he defied his prognosis with the help of an experimental, personalized cancer vaccine. His extraordinary recovery inspired the creation of a full research and clinical infrastructure to make such treatments accessible in the Netherlands.
Frank’s legacy made possible the launch of NeOncoFRAx and helped establish a sustainable path toward integrating personalized vaccine therapy into the standard of care. His legacy lives on in the organization’s name: Ne (neoantigen), Onco (oncology), FRAx (Frank + vaccine).
“In the spring of 2020, I was diagnosed with locally advanced pancreatic carcinoma, with the news that it was going to be quite a fight. After a second and a third opinion that both confirmed my lethal prognosis, I came into the hands of Prof van Eijck, but not after first completing an 8x chemotherapy course. Chemotherapy, often seen as unavoidable for this disease, has mainly been the reason to think about alternative treatments, as it not only proves destructive to the tumor but also affects your entire functioning. Thanks to Prof Van Eijck and a personalized vaccine, I am still here after 2.5 years. Unfortunately, such a vaccine is not available to everyone. I wish to change this with my investment through FRAGenVax and help others benefit from this treatment.”
“NeOncoFRAx reflects our belief that the future of cancer care lies in personalization, academic integrity, and patient access. What began as an individual patient’s extraordinary response has become a translational platform that unites prediction, production, and treatment under one roof. As clinicians, we are proud to contribute to a non-profit model that prioritizes transparency, collaboration, and meaningful patient impact.”